NCT02136511Approved For Marketing不适用
An Expanded Access Protocol for Idelalisib in Combination With Rituximab for Relapsed, Previously Treated Subjects With Chronic Lymphocytic Leukemia
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 8
研究概览
简要总结
This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 years of age with a diagnosis of B-cell CLL established according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and documented within medical records
- •CLL that warrants treatment (consistent with accepted IWCLL criteria for initiation of therapy)
- •Prior treatment for CLL comprising any of the following:
- •Prior treatment with ≥ 1 regimen containing a therapeutic anti-CD20 antibody or
- •Prior treatment with ≥ 2 regimens containing ≥ 1 cytotoxic agent
- •CLL progression < 24 months since the completion of the last prior therapy for CLL
- •Appropriate for noncytotoxic-containing therapy based on the presence of any of the following factors:
- •Grade ≥ 3 neutropenia or thrombocytopenia attributable to cumulative myelotoxicity from prior administration of cytotoxic agents (as documented by bone marrow biopsy obtained since last prior therapy), or
- •Estimated creatinine clearance < 60 mL/min (as determined by the Cockcroft-Gault method), or
- •A Cumulative Illness Rating Scale (CIRS) score of > 6
- •A negative serum pregnancy test for female subjects of childbearing potential
- •Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
- •Lactating females must agree to discontinue nursing before the study drug is administered.
- •Evidence of a personally signed informed consent
排除标准
- •Known hypersensitivity to the idelalisib, its metabolites, or formulation excipient(s)
- •Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
- •Known myelodysplastic syndrome
- •Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization
- •Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension
- •Ongoing drug-induced pneumonitis
- •Ongoing inflammatory bowel disease
- •History of anaphylaxis in association with previous administration of monoclonal antibodies
研究者
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to provide access to idelalisib in combination with rituximab for the treatment of previously treated chronic lymphocytic leukemiaChronic lymphocytic leukemiaMedDRA version: 19.0 Level: LLT Classification code 10068919 Term: B-cell chronic lymphocytic leukemia System Organ Class: 100000004864EUCTR2013-005343-82-GBGilead Sciences, Inc.31
进行中（未招募）
1 期
A study to provide access to idelalisib in combination with rituximab for the treatment of previously treated chronic lymphocytic leukemiaEUCTR2013-005343-82-IEGilead Sciences, Inc.150
进行中（未招募）
不适用
A study to provide access to idelalisib in combination with rituximab for the treatment of previously treated chronic lymphocytic leukemiaChronic lymphocytic leukemiaMedDRA version: 16.1Level: LLTClassification code 10068919Term: B-cell chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2013-005343-82-DEGilead Sciences, Inc.150
进行中（未招募）
1 期
A study to provide access to idelalisib in combination with rituximab for the treatment of previously treated chronic lymphocytic leukemiaEUCTR2013-005343-82-ITGilead Sciences, Inc.150
Available
不适用
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009Breast Neoplasm Malignant FemaleNCT05134922Celcuity Inc